139 related articles for article (PubMed ID: 30708392)
21. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
22. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
23. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
Heyborne KD; Allshouse AA
Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018
[TBL] [Abstract][Full Text] [Related]
24. Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention.
Wheeler S; DeNoble A; Wynn C; Weaver K; Swamy G; Janko M; Lantos P
J Racial Ethn Health Disparities; 2019 Jun; 6(3):563-569. PubMed ID: 30632084
[TBL] [Abstract][Full Text] [Related]
25. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
[TBL] [Abstract][Full Text] [Related]
26. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Kalata M; Teter K; Wagner L; Swarr V; Witzeman K
J Matern Fetal Neonatal Med; 2021 Feb; 34(4):541-546. PubMed ID: 31006296
[No Abstract] [Full Text] [Related]
27. Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.
Mazza GR; Komatsu E; Ponzio M; Bai C; Cortessis VK; Sasso EB
BMC Pregnancy Childbirth; 2024 Apr; 24(1):252. PubMed ID: 38589796
[TBL] [Abstract][Full Text] [Related]
28. 17 Alpha-hydroxyprogesterone caproate use in a rural state.
Ghahremani T; Phillips A; Magann EF; McCoy H; Whittington J; Ounpraseuth S; Eswaran H
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6437-6439. PubMed ID: 33899652
[TBL] [Abstract][Full Text] [Related]
29. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
30. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
[TBL] [Abstract][Full Text] [Related]
31. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
32. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice.
González-Quintero VH; de la Torre L; Rhea DJ; Tudela CM; Vazquez-Vera E; Desch C; Istwan NB
Am J Obstet Gynecol; 2010 Sep; 203(3):257.e1-5. PubMed ID: 20678745
[TBL] [Abstract][Full Text] [Related]
33. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
34. Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis.
Markham KB; Walker H; Lynch CD; Iams JD
Obstet Gynecol; 2014 Jan; 123(1):34-39. PubMed ID: 24463661
[TBL] [Abstract][Full Text] [Related]
35. Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
Greene MF; Klebanoff MA; Harrington D
N Engl J Med; 2020 Dec; 383(24):e130. PubMed ID: 33140924
[No Abstract] [Full Text] [Related]
36. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Prior Term Birth on Risk of Recurrent Spontaneous Preterm Birth.
Purisch SE; Turitz AL; Elovitz MA; Levine LD
Am J Perinatol; 2018 Mar; 35(4):380-384. PubMed ID: 29078234
[TBL] [Abstract][Full Text] [Related]
38. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
39. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
Zhang S; Rascati KL
Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
Manuck TA; Watkins WS; Esplin MS; Biggio J; Bukowski R; Parry S; Zhan H; Huang H; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J; Yandell M; Varner MW; Jorde LB;
BJOG; 2018 Feb; 125(3):343-350. PubMed ID: 28139890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
